Cell-Based Assays Keep Biosimilars on Track

The cell-based assay has become a mainstay of drug development, addressing new concerns raised by the advent of biologics. These concerns include the difficulties inherent in characterizing drug efficacy and patient safety in the context of immunogenicity. Whereas small molecule drugs may escape detection by the immune system, larger protein therapeutics, such as monoclonal antibodies, are apt to trigger alarms.

Click for full article

Featured Expert

Pharmacokinetics & Pharmacodynamics​

See how our PK expertise complements our immunogenicity services by evaluating absorption, distribution, metabolism and excretion characteristics of a product.
220328 Adleverage_Scientific Icon Illustrations_#46-65_CO_Per FIles